Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Autoimmune Disorders

  Free Subscription


Articles published in Kidney Int

Retrieve available abstracts of 149 articles:
HTML format



Single Articles


    April 2021
  1. FLOEGE J, Rovin BH
    The STARMEN trial: rethinking calcineurin inhibitor therapy in membranous nephropathy.
    Kidney Int. 2021;99:811-813.
    PubMed     Abstract available


  2. DELAFOSSE M, Ponlot E, Esteve E, Ghislain L, et al
    Personalized phospholipase A2 receptor antibody-driven rituximab treatment strategy in membranous nephropathy.
    Kidney Int. 2021;99:1023-1024.
    PubMed    


  3. FERNANDEZ-JUAREZ G, Rojas-Rivera J, Praga M
    The authors reply.
    Kidney Int. 2021;99:1024-1025.
    PubMed    


    March 2021
  4. ARTINGER K, Kirsch AH, Mooslechner AA, Cooper DJ, et al
    Blockade of tumor necrosis factor superfamily members CD30 and OX40 abrogates disease activity in murine immune-mediated glomerulonephritis.
    Kidney Int. 2021 Mar 27. pii: S0085-2538(21)00345.
    PubMed     Abstract available


  5. CRAVEDI P
    Complement in membranous nephropathy: what we thought we knew and what we really know.
    Kidney Int. 2021 Mar 24. pii: S0085-2538(21)00297.
    PubMed    


  6. NEGREA L, Rovin BH
    Gross Hematuria Following Vaccination for SARS-CoV2 in Two Patients with IgA Nephropathy.
    Kidney Int. 2021 Mar 23. pii: S0085-2538(21)00286.
    PubMed    


  7. ROBSON KJ, Kitching AR
    Recurrent membranous nephropathy after transplantation: donor antigen and HLA converge in defining risk.
    Kidney Int. 2021;99:545-548.
    PubMed     Abstract available


    February 2021
  8. LEI Y, Sehnert B, Voll RE, Jacobs-Cacha C, et al
    A multicenter blinded preclinical randomized controlled trial on Jak1/2 inhibition in MRL/MpJ-Fas(lpr) mice with proliferative lupus nephritis predicts low effect size.
    Kidney Int. 2021 Feb 16. pii: S0085-2538(21)00205.
    PubMed     Abstract available


  9. GINZLER EM
    Are new treatments for lupus nephritis on the horizon?
    Kidney Int. 2021;99:298-300.
    PubMed    


  10. ANDERS HJ, Lei Y, Rovin BH
    Induction and maintenance therapy of lupus nephritis: an obituary.
    Kidney Int. 2021;99:288-291.
    PubMed    


  11. COSTEDOAT-CHALUMEAU N, Houssiau FA
    Improving medication adherence in patients with lupus nephritis.
    Kidney Int. 2021;99:285-287.
    PubMed    


    January 2021
  12. PAWLUCZYK IZ, Didangelos A, Barbour SJ, Er L, et al
    Differential expression of microRNA miR-150-5p in IgA nephropathy as a potential mediator and marker of disease progression.
    Kidney Int. 2021 Jan 5. pii: S0085-2538(20)31553.
    PubMed     Abstract available


  13. FLOEGE J, Johnson RJ
    Hyperuricemia and progression of chronic kidney disease: to treat or not to treat?
    Kidney Int. 2021;99:14-16.
    PubMed    


    December 2020
  14. PERKINS GB, Kim J, Coates PT
    Going Rogue: how autoantibodies become pathogenic.
    Kidney Int. 2020 Dec 18. pii: S0085-2538(20)31522.
    PubMed    


    November 2020
  15. BARBOUR SJ, Coppo R, Er L, Russo ML, et al
    Updating the International IgA Nephropathy Prediction Tool for use in children.
    Kidney Int. 2020 Nov 18. pii: S0085-2538(20)31385.
    PubMed     Abstract available


  16. FERNANDEZ-JUAREZ G, Rojas-Rivera J, Logt AV, Justino J, et al
    The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy.
    Kidney Int. 2020 Nov 6. pii: S0085-2538(20)31251.
    PubMed     Abstract available


  17. HAYASHI N, Beck LH Jr
    Moore's law for membranous nephropathy.
    Kidney Int. 2020;98:1081-1084.
    PubMed     Abstract available


    October 2020
  18. CAZA T, Hassen S, Kuperman M, Sharma S, et al
    Neural cell adhesion molecule 1 is a novel autoantigen in membranous lupus nephritis.
    Kidney Int. 2020 Oct 9. pii: S0085-2538(20)31180.
    PubMed     Abstract available


  19. CHEUNG CK, Barratt J
    Should we STOP immunosuppression for IgA nephropathy? Long-term outcomes from the STOP-IgAN trial.
    Kidney Int. 2020;98:836-838.
    PubMed     Abstract available


  20. ODLER B, Flick H, Pollheimer MJ, Goritschan A, et al
    The Case | Glomerulonephritis in a patient with rheumatoid arthritis.
    Kidney Int. 2020;98:1057-1058.
    PubMed    


    September 2020
  21. PRENDECKI M, Clarke C, Cairns T, Cook T, et al
    Anti-glomerular basement membrane disease during the COVID-19 pandemic.
    Kidney Int. 2020;98:780-781.
    PubMed    


  22. BERCHTOLD L, Letouze E, Alexander MP, Canaud G, et al
    HLA-D and PLA2R1 risk alleles associate with recurrent primary membranous nephropathy in kidney transplant recipients.
    Kidney Int. 2020 Sep 1. pii: S0085-2538(20)30967.
    PubMed     Abstract available


    August 2020
  23. CAZA T, Hassen S, Dvanajscak Z, Kuperman M, et al
    NELL1 is a target antigen in malignancy-associated membranous nephropathy.
    Kidney Int. 2020 Aug 20. pii: S0085-2538(20)30956.
    PubMed     Abstract available


    July 2020
  24. IHARA K, Skupien J, Krolewski B, Md Dom ZI, et al
    A profile of multiple circulating tumor necrosis factor receptors associated with early progressive kidney decline in Type 1 Diabetes is similar to profiles in autoimmune disorders.
    Kidney Int. 2020 Jul 24. pii: S0085-2538(20)30834.
    PubMed     Abstract available


  25. JO HA, Hyeon JS, Yang SH, Jung Y, et al
    Fumarate modulates phospholipase A2 receptor autoimmunity-induced podocyte injury in membranous nephropathy.
    Kidney Int. 2020 Jul 23. pii: S0085-2538(20)30825.
    PubMed     Abstract available


    June 2020
  26. KURATA Y, Tanaka T, Nangaku M
    The role of hypoxia in the pathogenesis of lupus nephritis.
    Kidney Int. 2020 Jun 26. pii: S0085-2538(20)30702.
    PubMed    


  27. ABDIRAMA D, Tesch S, Griessbach AS, von Spee-Mayer C, et al
    Nuclear antigen-reactive CD4(+) T cells expand in active systemic lupus erythematosus, produce effector cytokines, and invade the kidneys.
    Kidney Int. 2020 Jun 24. pii: S0085-2538(20)30704.
    PubMed     Abstract available


  28. SETHI S, Debiec H, Madden B, Vivarelli M, et al
    Semaphorin 3B-associated membranous nephropathy is a distinct type of disease predominantly present in pediatric patients.
    Kidney Int. 2020 Jun 10. pii: S0085-2538(20)30640.
    PubMed     Abstract available


    May 2020
  29. BARBOUR SJ, Canney M, Coppo R, Zhang H, et al
    Improving treatment decisions using personalized risk assessment from the International IgA Nephropathy Prediction Tool.
    Kidney Int. 2020 May 25. pii: S0085-2538(20)30544.
    PubMed     Abstract available


  30. RAUEN T, Wied S, Fitzner C, Eitner F, et al
    After ten years of follow-up, no difference between supportive care plus immunosuppression and supportive care alone in IgA nephropathy.
    Kidney Int. 2020 May 22. pii: S0085-2538(20)30549.
    PubMed     Abstract available


  31. JONES BE, Herrera CA, Agosto-Burgos C, Starmer J, et al
    ANCA autoantigen gene expression highlights neutrophil heterogeneity where expression in normal-density neutrophils correlates with ANCA-induced activation.
    Kidney Int. 2020 May 21. pii: S0085-2538(20)30538.
    PubMed     Abstract available


  32. COUSER WG
    The pathogenesis of human membranous nephropathy: we are (almost) there.
    Kidney Int. 2020;97:849-852.
    PubMed     Abstract available


    April 2020
  33. YANG SR, Hua KF, Chu LJ, Hwu YK, et al
    Xenon blunts NF-kappaB/NLRP3 inflammasome activation and improves acute onset of accelerated and severe lupus nephritis in mice.
    Kidney Int. 2020 Apr 6. pii: S0085-2538(20)30357.
    PubMed     Abstract available


  34. PONTICELLI C, Moroni G
    Discontinuation of therapy in lupus nephritis.
    Kidney Int. 2020;97:806-807.
    PubMed    


  35. MALVAR A, Rovin BH
    The authors reply.
    Kidney Int. 2020;97:807.
    PubMed    


    March 2020
  36. SAID SM, Leung N, Alexander MP, Cornell LD, et al
    DNAJB9-positive monotypic fibrillary glomerulonephritis is not associated with monoclonal gammopathy in the vast majority of patients.
    Kidney Int. 2020 Mar 28. pii: S0085-2538(20)30267.
    PubMed     Abstract available


    February 2020
  37. SCINDIA Y, Wlazlo E, Ghias E, Cechova S, et al
    Modulation of iron homeostasis with hepcidin ameliorates spontaneous murine lupus nephritis.
    Kidney Int. 2020 Feb 17. pii: S0085-2538(20)30139.
    PubMed     Abstract available


  38. TANG J, Liao Z, Meng T, Ning J, et al
    The Case | Glomerulonephritis with prolonged recurrent fever.
    Kidney Int. 2020;97:427-428.
    PubMed    


  39. ROVIN BH
    Systemic autoimmune diseases and the kidney.
    Kidney Int. 2020;97:222-225.
    PubMed    


  40. TSOKOS GC
    Notch notches lupus.
    Kidney Int. 2020;97:251-253.
    PubMed     Abstract available


  41. SUGAHARA M, Tanaka T, Nangaku M
    Modulating the immune system to delay the clinical onset of type 1 diabetes.
    Kidney Int. 2020;97:248-250.
    PubMed    


    January 2020
  42. CRICKX E, Weill JC, Reynaud CA, Mahevas M, et al
    Anti-CD20-mediated B-cell depletion in autoimmune diseases: successes, failures and future perspectives.
    Kidney Int. 2020 Jan 30. pii: S0085-2538(20)30108.
    PubMed     Abstract available


  43. AHMAD SB, Appel GB
    Antigens, antibodies, and membranous nephropathy: a decade of progress.
    Kidney Int. 2020;97:29-31.
    PubMed     Abstract available


  44. JAYNE D, Bajema IM
    "In my beginning is my end": usefulness of repeat kidney biopsies in lupus nephritis.
    Kidney Int. 2020;97:27-29.
    PubMed     Abstract available


  45. SETHI S, Debiec H, Madden B, Charlesworth MC, et al
    Neural epidermal growth factor-like 1 protein (NELL-1) associated membranous nephropathy.
    Kidney Int. 2020;97:163-174.
    PubMed     Abstract available


    November 2019
  46. NASR SH, Larsen CP, Sirac C, Theis JD, et al
    Light chain only variant of proliferative glomerulonephritis with monoclonal immunoglobulin deposits is associated with a high detection rate of the pathogenic plasma cell clone.
    Kidney Int. 2019 Nov 9. pii: S0085-2538(19)31118.
    PubMed     Abstract available


  47. MEYER-SCHWESINGER C, Tomas NM, Dehde S, Seifert L, et al
    A novel mouse model of phospholipase A2 receptor 1-associated membranous nephropathy mimics podocyte injury in patients.
    Kidney Int. 2019 Nov 9. pii: S0085-2538(19)31115.
    PubMed     Abstract available


  48. LUQUE A, Serrano I, Ripoll E, Malta C, et al
    Noncanonical immunomodulatory activity of complement regulator C4BP(beta-) limits the development of lupus nephritis.
    Kidney Int. 2019 Nov 6. pii: S0085-2538(19)31049.
    PubMed     Abstract available


    October 2019
  49. BREITKOPF DM, Jankowski V, Ohl K, Hermann J, et al
    The YB-1:Notch-3 axis modulates immune cell responses and organ damage in systemic lupus erythematosus.
    Kidney Int. 2019 Oct 30. pii: S0085-2538(19)31039.
    PubMed     Abstract available


  50. SMITH JR, Methven S, Stevens KI, MacKinnon B, et al
    Renal risk score performance in a cohort of Scottish patients with ANCA-associated glomerulonephritis.
    Kidney Int. 2019;96:1037.
    PubMed    


    September 2019
  51. MAKITA Y, Suzuki H, Kano T, Takahata A, et al
    TLR9 activation induces aberrant IgA glycosylation via APRIL- and IL-6-mediated pathways in IgA nephropathy.
    Kidney Int. 2019 Sep 5. pii: S0085-2538(19)30849.
    PubMed     Abstract available


  52. ARAUJO SA, Neves PDMM, Wanderley DC, Reis MAD, et al
    The immunohistological profile of membranous nephropathy associated with chronic Schistosoma mansoni infection reveals a glomerulopathy with primary features.
    Kidney Int. 2019;96:793-794.
    PubMed    


  53. WILLIAMS ME
    Said the glucose sensor to the insulin pump: can glycemic control be improved in hospitalized ESRD patients with diabetes mellitus?
    Kidney Int. 2019;96:540-542.
    PubMed     Abstract available


    August 2019
  54. MALVAR A, Alberton V, Lococo B, Ferrari M, et al
    Kidney biopsy-based management of maintenance immunosuppression is safe and may ameliorate flare rate in lupus nephritis.
    Kidney Int. 2019 Aug 20. pii: S0085-2538(19)30816.
    PubMed     Abstract available


  55. VAN DE LOGT AE, Fresquet M, Wetzels JF, Brenchley P, et al
    The anti-PLA2R antibody in membranous nephropathy: what we know and what remains a decade after its discovery.
    Kidney Int. 2019 Aug 12. pii: S0085-2538(19)30807.
    PubMed     Abstract available


  56. FLOEGE J
    A new tool to predict the risk of progression in IgA nephropathy.
    Kidney Int. 2019 Aug 1. pii: S0085-2538(19)30776.
    PubMed    


    July 2019
  57. BAGCHI S, Behera V, Agarwal SK
    ACTH (corticotrophin) therapy in resistant primary membranous nephropathy.
    Kidney Int. 2019;96:250-251.
    PubMed    


  58. WESTER TREJO MAC, van Daalen EE, Berden AE, Wolterbeek R, et al
    A renal risk score for ANCA-associated glomerulonephritis.
    Kidney Int. 2019;96:245.
    PubMed    


    May 2019
  59. GAN PY, Chan A, Ooi JD, Dick J, et al
    Biologicals targeting T helper cell subset differentiating cytokines are effective in the treatment of murine anti-myeloperoxidase glomerulonephritis.
    Kidney Int. 2019 May 27. pii: S0085-2538(19)30531.
    PubMed     Abstract available


  60. KODAMA Y, Hyodo F, Yamato M, Yasukawa K, et al
    Dynamic nuclear polarization magnetic resonance imaging and the oxygen-sensitive paramagnetic agent OX63 provide a noninvasive quantitative evaluation of kidney hypoxia in diabetic mice.
    Kidney Int. 2019 May 24. pii: S0085-2538(19)30515.
    PubMed     Abstract available


  61. OKABAYASHI Y, Nagasaka S, Kanzaki G, Tsuboi N, et al
    Group 1 innate lymphoid cells are involved in the progression of experimental anti-glomerular basement membrane glomerulonephritis and are regulated by peroxisome proliferator-activated receptor alpha.
    Kidney Int. 2019 May 22. pii: S0085-2538(19)30523.
    PubMed     Abstract available


  62. NASR SH, Dasari S, Lieske JC, Benson LM, et al
    Serum levels of DNAJB9 are elevated in fibrillary glomerulonephritis patients.
    Kidney Int. 2019;95:1269-1272.
    PubMed     Abstract available


  63. ANDEEN NK
    Elevated serum concentrations of DNAJB9 in fibrillary glomerulonephritis: another step toward understanding a progressive disease.
    Kidney Int. 2019;95:1025-1026.
    PubMed     Abstract available


    April 2019
  64. NASR SH, Fogo AB
    New developments in the diagnosis of fibrillary glomerulonephritis.
    Kidney Int. 2019 Apr 9. pii: S0085-2538(19)30407.
    PubMed     Abstract available


  65. TRIMARCHI H, Barratt J, Monteiro RC, Feehally J, et al
    IgA nephropathy: "State of the art": a report from the 15th International Symposium on IgA Nephropathy celebrating the 50th anniversary of its first description.
    Kidney Int. 2019;95:750-756.
    PubMed     Abstract available


  66. BARBOUR S, Djurdjev O, Gill JS, Dong JJ, et al
    A propensity score matched analysis shows no adverse effect of early steroid withdrawal in non-diabetic kidney transplant recipients with and without glomerulonephritis.
    Kidney Int. 2019 Apr 1. pii: S0085-2538(19)30388.
    PubMed     Abstract available


  67. ROVIN BH, Solomons N, Huizinga RB
    The authors reply.
    Kidney Int. 2019;95:992-993.
    PubMed    


  68. TRACHTMAN H, Caplan AL
    Data monitoring committees and randomized clinical trials.
    Kidney Int. 2019;95:992.
    PubMed    


    March 2019
  69. MYETTE JR, Kano T, Suzuki H, Sloan SE, et al
    A Proliferation Inducing Ligand (APRIL) targeted antibody is a safe and effective treatment of murine IgA nephropathy.
    Kidney Int. 2019 Mar 16. pii: S0085-2538(19)30174.
    PubMed     Abstract available


  70. CANNEY M, Induruwage D, McCandless LC, Reich HN, et al
    Disease-specific incident glomerulonephritis displays geographic clustering in under-serviced rural areas of British Columbia, Canada.
    Kidney Int. 2019 Mar 15. pii: S0085-2538(19)30315.
    PubMed     Abstract available


  71. PUELLES VG, Fleck D, Ortz L, Papadouri S, et al
    Novel 3D analysis using optical tissue clearing documents the evolution of murine rapidly progressive glomerulonephritis.
    Kidney Int. 2019 Mar 15. pii: S0085-2538(19)30318.
    PubMed     Abstract available


  72. ZAGHRINI C, Seitz-Polski B, Justino J, Dolla G, et al
    Novel ELISA for thrombospondin type 1 domain-containing 7A autoantibodies in membranous nephropathy.
    Kidney Int. 2019;95:666-679.
    PubMed     Abstract available


  73. NAKAMURA J, Sato Y, Kitai Y, Wajima S, et al
    Myofibroblasts acquire retinoic acid-producing ability during fibroblast-to-myofibroblast transition following kidney injury.
    Kidney Int. 2019;95:526-539.
    PubMed     Abstract available


    February 2019
  74. KOUSIOS A, Duncan N, Tam FWK, Chaidos A, et al
    Proliferative glomerulonephritis with monoclonal Ig deposits (PGNMID): diagnostic and treatment challenges for the nephrologist!
    Kidney Int. 2019;95:467-468.
    PubMed    


  75. BOBART SA, De Vriese AS, Pawar AS, Zand L, et al
    Noninvasive diagnosis of primary membranous nephropathy using phospholipase A2 receptor antibodies.
    Kidney Int. 2019;95:429-438.
    PubMed     Abstract available


  76. ROVIN BH, Almaani S, Malvar A
    Reimagining the kidney biopsy in the era of diagnostic biomarkers of glomerular disease.
    Kidney Int. 2019;95:265-267.
    PubMed     Abstract available


  77. WANG L, Chang JH, Buckley AF, Spurney RF, et al
    Knockout of TRPC6 promotes insulin resistance and exacerbates glomerular injury in Akita mice.
    Kidney Int. 2019;95:321-332.
    PubMed     Abstract available


  78. ROVIN BH, Caster DJ, Cattran DC, Gibson KL, et al
    Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.
    Kidney Int. 2019;95:281-295.
    PubMed     Abstract available


  79. FLOEGE J, Barbour SJ, Cattran DC, Hogan JJ, et al
    Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.
    Kidney Int. 2019;95:268-280.
    PubMed     Abstract available


    January 2019
  80. KITAGAWA A, Tsuboi N, Yokoe Y, Katsuno T, et al
    Urinary levels of the leukocyte surface molecule CD11b associate with glomerular inflammation in lupus nephritis.
    Kidney Int. 2019 Jan 26. pii: S0085-2538(18)30826.
    PubMed     Abstract available


  81. WILSON HR, Medjeral-Thomas NR, Gilmore AC, Trivedi P, et al
    Glomerular membrane attack complex is not a reliable marker of ongoing C5 activation in lupus nephritis.
    Kidney Int. 2019 Jan 8. pii: S0085-2538(18)30789.
    PubMed     Abstract available


  82. DAHAN K, Johannet C, Esteve E, Plaisier E, et al
    Retreatment with rituximab for membranous nephropathy with persistently elevated titers of anti-phospholipase A2 receptor antibody.
    Kidney Int. 2019;95:233-234.
    PubMed    


  83. CRAIG JC
    Interpreting trial results-time for confidence and magnitude and not P values please.
    Kidney Int. 2019;95:28-30.
    PubMed     Abstract available


    December 2018
  84. KRONBICHLER A, Jayne DRW
    ANCA Renal Risk Score: is prediction of end-stage renal disease at baseline possible?
    Kidney Int. 2018;94:1045-1047.
    PubMed     Abstract available


    November 2018
  85. KASINATH V, Yilmam OA, Uehara M, Jiang L, et al
    Activation of fibroblastic reticular cells in kidney lymph node during crescentic glomerulonephritis.
    Kidney Int. 2018 Nov 29. pii: S0085-2538(18)30647.
    PubMed     Abstract available


  86. ROVIN BH, Solomons N, Pendergraft WF 3rd, Dooley MA, et al
    A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis.
    Kidney Int. 2018 Nov 5. pii: S0085-2538(18)30628.
    PubMed     Abstract available


  87. BECK LH JR, Salant DJ
    Deep pockets are not necessarily a good thing in membranous nephropathy: evidence for a modifier allele.
    Kidney Int. 2018;94:855-857.
    PubMed     Abstract available


    October 2018
  88. MULLER MB, Hoppe JM, Bideak A, Lux M, et al
    Exclusive expression of transmembrane TNF aggravates acute glomerulonephritis despite reduced leukocyte infiltration and inflammation.
    Kidney Int. 2018 Oct 30. pii: S0085-2538(18)30594.
    PubMed     Abstract available


  89. BRIX SR, Noriega M, Tennstedt P, Vettorazzi E, et al
    Development and validation of a renal risk score in ANCA-associated glomerulonephritis.
    Kidney Int. 2018 Oct 23. pii: S0085-2538(18)30552.
    PubMed     Abstract available


  90. RAMACHANDRAN R, Yadav AK, Sethi J, Gupta KL, et al
    Antibodies to M-type phospholipase receptor and immunological remission in treatment-resistant and relapsing membranous nephropathy.
    Kidney Int. 2018;94:829-830.
    PubMed    


  91. NACHMAN PH
    Repeat kidney biopsy for lupus nephritis: an important step forward.
    Kidney Int. 2018;94:659-661.
    PubMed     Abstract available


  92. VAN DE LOGT AE, Dahan K, Ronco P, Wetzels J, et al
    The authors reply.
    Kidney Int. 2018;94:830.
    PubMed    


    August 2018
  93. WANG HY, Cui Z, Xie LJ, Zhang LJ, et al
    HLA class II alleles differing by a single amino acid associate with clinical phenotype and outcome in patients with primary membranous nephropathy.
    Kidney Int. 2018 Aug 26. pii: S0085-2538(18)30441.
    PubMed     Abstract available


    July 2018
  94. DE ROSA M, Azzato F, Toblli JE, De Rosa G, et al
    A prospective observational cohort study highlights kidney biopsy findings of lupus nephritis patients in remission who flare following withdrawal of maintenance therapy.
    Kidney Int. 2018 Jul 20. pii: S0085-2538(18)30395.
    PubMed     Abstract available


  95. FLOEGE J, Daha MR
    IgA nephropathy: new insights into the role of complement.
    Kidney Int. 2018;94:16-18.
    PubMed     Abstract available


    June 2018
  96. ARKATKAR T, Jacobs HM, Du SW, Li QZ, et al
    TACI deletion protects against progressive murine lupus nephritis induced by BAFF overexpression.
    Kidney Int. 2018 Jun 12. pii: S0085-2538(18)30252.
    PubMed     Abstract available


  97. ROPS ALWMM, Jansen E, van der Schaaf A, Pieterse E, et al
    Interleukin-6 is essential for glomerular immunoglobulin A deposition and the development of renal pathology in Cd37-deficient mice.
    Kidney Int. 2018;93:1356-1366.
    PubMed     Abstract available


    May 2018
  98. SAHA MK, Julian BA, Novak J, Rizk DV, et al
    Secondary IgA nephropathy.
    Kidney Int. 2018 May 24. pii: S0085-2538(18)30245.
    PubMed     Abstract available


  99. ZHU L, Guo WY, Shi SF, Liu LJ, et al
    Circulating complement factor H-related protein 5 levels contribute to development and progression of IgA nephropathy.
    Kidney Int. 2018 May 11. pii: S0085-2538(18)30214.
    PubMed     Abstract available


  100. GUMBER R, Cohen JB, Palmer MB, Kobrin SM, et al
    A clone-directed approach may improve diagnosis and treatment of proliferative glomerulonephritis with monoclonal immunoglobulin deposits.
    Kidney Int. 2018 May 11. pii: S0085-2538(18)30211.
    PubMed     Abstract available


  101. LIM CC, Choo JCJ, Chan CM, Woo KT, et al
    Age-adjusted global glomerulosclerosis in addition to Oxford histological classification of IgA nephropathy.
    Kidney Int. 2018;93:1250.
    PubMed    


  102. NADA R, Ramachandran R, Kumar A, Gupta KL, et al
    Tumoral masses in failed kidneys.
    Kidney Int. 2018;93:1253.
    PubMed    


  103. DESIDERI S, Onions KL, Qiu Y, Ramnath RD, et al
    A novel assay provides sensitive measurement of physiologically relevant changes in albumin permeability in isolated human and rodent glomeruli.
    Kidney Int. 2018;93:1086-1097.
    PubMed     Abstract available


  104. HOMMOS MS, Zeng C, Liu Z, Troost JP, et al
    Global glomerulosclerosis with nephrotic syndrome; the clinical importance of age adjustment.
    Kidney Int. 2018;93:1175-1182.
    PubMed     Abstract available


    April 2018
  105. SAID SM, Cosio FG, Valeri AM, Leung N, et al
    Proliferative glomerulonephritis with monoclonal immunoglobulin G deposits is associated with high rate of early recurrence in the allograft.
    Kidney Int. 2018 Apr 28. pii: S0085-2538(18)30175.
    PubMed     Abstract available


  106. ELLER K, Rosenkranz AR
    Atypical chemokine receptors-"chemokine PACMANs" as new therapeutic targets in glomerulonephritis.
    Kidney Int. 2018;93:774-775.
    PubMed     Abstract available



  107. Fu J, Wang Z, Lee K, et al. Transcriptomic analysis uncovers novel synergistic mechanisms in combination therapy for lupus nephritis. Kidney Int. 2018;93:416-429.
    Kidney Int. 2018;93:1018.
    PubMed    


  108. VAN DE LOGT AE, Dahan K, Rousseau A, van der Molen R, et al
    Immunological remission in PLA2R-antibody-associated membranous nephropathy: cyclophosphamide versus rituximab.
    Kidney Int. 2018;93:1016-1017.
    PubMed    


    March 2018
  109. FLOEGE J
    IgA nephropathy: toward more specific diagnosis (and rescue of snails).
    Kidney Int. 2018;93:542-544.
    PubMed     Abstract available


  110. LAUSECKER F, Tian X, Inoue K, Wang Z, et al
    Vinculin is required to maintain glomerular barrier integrity.
    Kidney Int. 2018;93:643-655.
    PubMed     Abstract available


    February 2018
  111. HONG Q, Zhang L, Das B, Li Z, et al
    Increased podocyte Sirtuin-1 function attenuates diabetic kidney injury.
    Kidney Int. 2018 Feb 22. pii: S0085-2538(18)30033.
    PubMed     Abstract available


  112. BAJEMA IM, Wilhelmus S, Alpers CE, Bruijn JA, et al
    Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices.
    Kidney Int. 2018 Feb 16. pii: S0085-2538(17)30859.
    PubMed     Abstract available


  113. MOON JS, Mun CH, Kim JH, Cho JY, et al
    Intranuclear delivery of the transcription modulation domain of Tbet-improved lupus nephritis in (NZB/NZW) F1 lupus-prone mice.
    Kidney Int. 2018 Feb 3. pii: S0085-2538(17)30853.
    PubMed     Abstract available


    January 2018
  114. BIDEAK A, Blaut A, Hoppe JM, Muller MB, et al
    The atypical chemokine receptor 2 limits renal inflammation and fibrosis in murine progressive immune complex glomerulonephritis.
    Kidney Int. 2018 Jan 22. pii: S0085-2538(17)30829.
    PubMed     Abstract available


  115. SUZUKI H, Yasutake J, Makita Y, Tanbo Y, et al
    IgA nephropathy and IgA vasculitis with nephritis have a shared feature involving galactose-deficient IgA1-oriented pathogenesis.
    Kidney Int. 2018 Jan 9. pii: S0085-2538(17)30799.
    PubMed     Abstract available


  116. BOMBACK AS, Santoriello D, Avasare RS, Regunathan-Shenk R, et al
    C3 glomerulonephritis and dense deposit disease share a similar disease course in a large United States cohort of patients with C3 glomerulopathy.
    Kidney Int. 2018 Jan 6. pii: S0085-2538(17)30802.
    PubMed     Abstract available


  117. STOKES MB, D'Agati VD
    Full-house glomerular deposits: beware the sheep in wolf's clothing.
    Kidney Int. 2018;93:18-20.
    PubMed     Abstract available


  118. RIJNINK EC, Teng YKO, Kraaij T, Dekkers OM, et al
    Validation of the Systemic Lupus International Collaborating Clinics classification criteria in a cohort of patients with full house glomerular deposits.
    Kidney Int. 2018;93:214-220.
    PubMed     Abstract available


  119. LIANG G, Song L, Chen Z, Qian Y, et al
    Fibroblast growth factor 1 ameliorates diabetic nephropathy by an anti-inflammatory mechanism.
    Kidney Int. 2018;93:95-109.
    PubMed     Abstract available


    December 2017
  120. EYMAEL J, Sharma S, Loeven MA, Wetzels JF, et al
    CD44 is required for the pathogenesis of experimental crescentic glomerulonephritis and collapsing focal segmental glomerulosclerosis.
    Kidney Int. 2017 Dec 21. pii: S0085-2538(17)30770.
    PubMed     Abstract available


  121. DICK J, Gan PY, Ford SL, Odobasic D, et al
    C5a receptor 1 promotes autoimmunity, neutrophil dysfunction and injury in experimental anti-myeloperoxidase glomerulonephritis.
    Kidney Int. 2017 Dec 11. pii: S0085-2538(17)30768.
    PubMed     Abstract available


    November 2017
  122. AMANN K
    Do ANCAs make the difference in lupus nephritis?
    Kidney Int. 2017;92:1048-1050.
    PubMed     Abstract available


  123. FU J, Wang Z, Lee K, Wei C, et al
    Transcriptomic analysis uncovers novel synergistic mechanisms in combination therapy for lupus nephritis.
    Kidney Int. 2017 Nov 1. pii: S0085-2538(17)30671.
    PubMed     Abstract available


    October 2017
  124. THURMAN JM, Laskowski J
    Complement factor H-related proteins in IgA nephropathy-sometimes a gentle nudge does the trick.
    Kidney Int. 2017;92:790-793.
    PubMed     Abstract available


    September 2017
  125. SINGH G, Bhardwaj S, Singh L, Sinha A, et al
    Proliferative glomerulonephritis with monotypic IgA-kappa deposits in a 10-year-old.
    Kidney Int. 2017;92:765-766.
    PubMed    


    August 2017
  126. DE FIJTER JW
    Recurrence of glomerulonephritis: an underestimated and unmet medical need.
    Kidney Int. 2017;92:294-296.
    PubMed     Abstract available


  127. FLOEGE J
    Mucosal corticosteroid therapy of IgA nephropathy.
    Kidney Int. 2017;92:278-280.
    PubMed     Abstract available


    July 2017
  128. DAI Y, Chen A, Liu R, Gu L, et al
    Retinoic acid improves nephrotoxic serum-induced glomerulonephritis through activation of podocyte retinoic acid receptor alpha.
    Kidney Int. 2017 Jul 27. pii: S0085-2538(17)30321.
    PubMed     Abstract available


  129. BROCKLEBANK V, Johnson S, Sheerin TP, Marks SD, et al
    Factor H autoantibody is associated with atypical hemolytic uremic syndrome in children in the United Kingdom and Ireland.
    Kidney Int. 2017 Jul 24. pii: S0085-2538(17)30323.
    PubMed     Abstract available


  130. TURNER-STOKES T, Wilson HR, Morreale M, Nunes A, et al
    Positive antineutrophil cytoplasmic antibody serology in patients with lupus nephritis is associated with distinct histopathologic features on renal biopsy.
    Kidney Int. 2017 Jul 24. pii: S0085-2538(17)30324.
    PubMed     Abstract available


  131. GALSGAARD J, Persson F, Hansen TW, Jorsal A, et al
    Plasma high-sensitivity troponin T predicts end-stage renal disease and cardiovascular and all-cause mortality in patients with type 1 diabetes and diabetic nephropathy.
    Kidney Int. 2017 Jul 13. pii: S0085-2538(17)30310.
    PubMed     Abstract available


  132. BOJIC M, Kozakowski N, Becede M, Kerschbaumer A, et al
    The Case | Myeloid bodies in the kidney biopsy of a patient with systemic lupus erythematosus.
    Kidney Int. 2017;92:271-272.
    PubMed    


    June 2017
  133. MEDJERAL-THOMAS NR, Lomax-Browne HJ, Beckwith H, Willicombe M, et al
    Circulating complement factor H-related proteins 1 and 5 correlate with disease activity in IgA nephropathy.
    Kidney Int. 2017 Jun 30. pii: S0085-2538(17)30256.
    PubMed     Abstract available


  134. TORTAJADA A, Gutierrez E, Goicoechea de Jorge E, Anter J, et al
    Elevated factor H-related protein 1 and factor H pathogenic variants decrease complement regulation in IgA nephropathy.
    Kidney Int. 2017 Jun 18. pii: S0085-2538(17)30254.
    PubMed     Abstract available


  135. ALLEN PJ, Chadban SJ, Craig JC, Lim WH, et al
    Recurrent glomerulonephritis after kidney transplantation: risk factors and allograft outcomes.
    Kidney Int. 2017 Jun 7. pii: S0085-2538(17)30208.
    PubMed     Abstract available


  136. VAN LAECKE S, Van Biesen W
    Severe hypertension with renal thrombotic microangiopathy: what happened to the usual suspect?
    Kidney Int. 2017;91:1271-1274.
    PubMed     Abstract available


    May 2017
  137. GUL A, Harford A, Zager P
    Mendelian randomization to establish the causality of uric acid with diabetic nephropathy in type 1 diabetics.
    Kidney Int. 2017;91:1005-1007.
    PubMed     Abstract available


    April 2017
  138. YAMANOUCHI M, Skupien J, Niewczas MA, Smiles AM, et al
    Improved clinical trial enrollment criterion to identify patients with diabetes at risk of end-stage renal disease.
    Kidney Int. 2017 Apr 7. pii: S0085-2538(17)30112.
    PubMed     Abstract available


    March 2017
  139. KROLEWSKI AS, Skupien J, Rossing P, Warram JH, et al
    Fast renal decline to end-stage renal disease: an unrecognized feature of nephropathy in diabetes.
    Kidney Int. 2017 Mar 30. pii: S0085-2538(17)30081.
    PubMed     Abstract available


  140. TRIMARCHI H, Barratt J, Cattran DC, Cook HT, et al
    Oxford Classification of IgA nephropathy 2016-the role of crescentic lesions: an update from the IgA Nephropathy Classification Working Group.
    Kidney Int. 2017 Mar 21. pii: S0085-2538(17)30101.
    PubMed     Abstract available


  141. ROSENZWAJG M, Languille E, Debiec H, Hygino J, et al
    B- and T-cell subpopulations in patients with severe idiopathic membranous nephropathy may predict an early response to rituximab.
    Kidney Int. 2017 Mar 15. pii: S0085-2538(17)30039.
    PubMed     Abstract available


  142. VIGNON M, Cohen C, Faguer S, Noel LH, et al
    The clinicopathologic characteristics of kidney diseases related to monotypic IgA deposits.
    Kidney Int. 2017;91:720-728.
    PubMed     Abstract available


  143. HE X, Cheng R, Park K, Benyajati S, et al
    Pigment epithelium-derived factor, a noninhibitory serine protease inhibitor, is renoprotective by inhibiting the Wnt pathway.
    Kidney Int. 2017;91:642-657.
    PubMed     Abstract available


    February 2017
  144. AHOLA AJ, Sandholm N, Forsblom C, Harjutsalo V, et al
    The serum uric acid concentration is not causally linked to diabetic nephropathy in type 1 diabetes.
    Kidney Int. 2017 Feb 21. pii: S0085-2538(16)30757.
    PubMed     Abstract available


    January 2017
  145. KLEMIS V, Ghura H, Federico G, Wurfel C, et al
    Circulating fibronectin contributes to mesangial expansion in a murine model of type 1 diabetes.
    Kidney Int. 2017 Jan 31. pii: S0085-2538(16)30706.
    PubMed     Abstract available


    December 2016
  146. KIM CS, Bae EH, Ma SK, Kim SW, et al
    The Case | Seizure, ophthalmoplegia, and amnesia in a peritoneal dialysis patient.
    Kidney Int. 2016;90:1389-1390.
    PubMed    


    November 2016
  147. YOU H, Gao T, Raup-Konsavage WM, Cooper TK, et al
    Podocyte-specific chemokine (C-C motif) receptor 2 overexpression mediates diabetic renal injury in mice.
    Kidney Int. 2016 Nov 30. pii: S0085-2538(16)30598.
    PubMed     Abstract available


    July 2016
  148. TAKASHIMA S, Fujita H, Fujishima H, Shimizu T, et al
    Stromal cell-derived factor-1 is upregulated by dipeptidyl peptidase-4 inhibition and has protective roles in progressive diabetic nephropathy.
    Kidney Int. 2016 Jul 27. pii: S0085-2538(16)30273.
    PubMed     Abstract available


    April 2016
  149. KLESSENS CQ, Woutman TD, Veraar KA, Zandbergen M, et al
    An autopsy study suggests that diabetic nephropathy is underdiagnosed.
    Kidney Int. 2016 Apr 9. pii: S0085-2538(16)00313.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Autoimmune Disorders is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: